Liesbeth Fagard Selected Research

GLPG1690

10/2019	Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
1/2019	Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
1/2018	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Liesbeth Fagard Research Topics

Disease

3	Idiopathic Pulmonary Fibrosis 10/2019 - 01/2018
1	Rheumatoid Arthritis 12/2018
1	Crohn Disease (Crohn's Disease) 12/2018
1	Cholangiocarcinoma 01/2018
1	Atrioventricular Block 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018
1	Infections 01/2018
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018

Drug/Important Bio-Agent (IBA)

3	GLPG1690IBA 10/2019 - 01/2018
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2019
1	lysophosphatidic acidIBA 01/2019
1	Janus Kinase 1IBA 12/2018
1	GLPG0634IBA 12/2018